Trial Profile
A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-611 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part 3) of Single Ascending Doses in Healthy Volunteers (Parts 1-2), and Multiple Ascending Doses in Subjects With Chronic Hepatitis C Virus Infection (Part 3)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AL-611 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors Alios BioPharma
- 23 Oct 2017 Status changed from recruiting to discontinued due to Strategic decision that discontinued further development of investigational compounds for the treatment of hepatitis C
- 22 Aug 2017 New trial record